147 related articles for article (PubMed ID: 9548820)
1. Epidoxoform: a hydrolytically more stable anthracycline-formaldehyde conjugate toxic to resistant tumor cells.
Taatjes DJ; Fenick DJ; Koch TH
J Med Chem; 1998 Apr; 41(8):1306-14. PubMed ID: 9548820
[TBL] [Abstract][Full Text] [Related]
2. Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
Fenick DJ; Taatjes DJ; Koch TH
J Med Chem; 1997 Aug; 40(16):2452-61. PubMed ID: 9258351
[TBL] [Abstract][Full Text] [Related]
3. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
Taatjes DJ; Fenick DJ; Koch TH
Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of epidoxorubicin-formaldehyde virtual crosslink of DNA and evidence for its formation in human breast-cancer cells.
Podell ER; Harrington DJ; Taatjes DJ; Koch TH
Acta Crystallogr D Biol Crystallogr; 1999 Sep; 55(Pt 9):1516-23. PubMed ID: 10489446
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibition, nuclear uptake, and retention of anthracycline-formaldehyde conjugates in prostate cancer cells relative to clinical anthracyclines.
Taatjes DJ; Koch TH
Anticancer Res; 1999; 19(2A):1201-8. PubMed ID: 10368676
[TBL] [Abstract][Full Text] [Related]
6. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells.
Taatjes DJ; Koch TH
Curr Med Chem; 2001 Jan; 8(1):15-29. PubMed ID: 11172689
[TBL] [Abstract][Full Text] [Related]
7. Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
Taatjes DJ; Gaudiano G; Resing K; Koch TH
J Med Chem; 1997 Apr; 40(8):1276-86. PubMed ID: 9111302
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the epidoxorubicin--formaldehyde conjugate, epidoxoform, in a mouse mammary carcinoma model.
Dernell WS; Powers BE; Taatjes DJ; Cogan P; Gaudiano G; Koch TH
Cancer Invest; 2002; 20(5-6):713-24. PubMed ID: 12197227
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of a new bisintercalating anthracycline antibiotic.
Chaires JB; Leng F; Przewloka T; Fokt I; Ling YH; Perez-Soler R; Priebe W
J Med Chem; 1997 Jan; 40(3):261-6. PubMed ID: 9022792
[TBL] [Abstract][Full Text] [Related]
10. Doxazolidine, a proposed active metabolite of doxorubicin that cross-links DNA.
Post GC; Barthel BL; Burkhart DJ; Hagadorn JR; Koch TH
J Med Chem; 2005 Dec; 48(24):7648-57. PubMed ID: 16302805
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
12. Production of formaldehyde and DNA-adriamycin or DNA-daunomycin adducts, initiated through redox chemistry of dithiothreitol/iron, xanthine oxidase/NADH/iron, or glutathione/iron.
Taatjes DJ; Gaudiano G; Koch TH
Chem Res Toxicol; 1997 Sep; 10(9):953-61. PubMed ID: 9305576
[TBL] [Abstract][Full Text] [Related]
13. Structural requirements for the formation of anthracycline-DNA adducts.
Cutts SM; Parker BS; Swift LP; Kimura KI; Phillips DR
Anticancer Drug Des; 2000 Oct; 15(5):373-86. PubMed ID: 11354313
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
Burke PJ; Koch TH
Anticancer Res; 2001; 21(4A):2753-60. PubMed ID: 11724351
[TBL] [Abstract][Full Text] [Related]
15. Influence of the structure of new anthracycline antibiotics on their biological properties.
Wasowska M; Oszczapowicz I; Wietrzyk J; Opolski A; Madej J; Dzimira S; Oszczapowicz J
Anticancer Res; 2005; 25(3B):2043-8. PubMed ID: 16158943
[TBL] [Abstract][Full Text] [Related]
16. The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.
Forrest RA; Swift LP; Evison BJ; Rephaeli A; Nudelman A; Phillips DR; Cutts SM
Cancer Chemother Pharmacol; 2013 Mar; 71(3):809-16. PubMed ID: 23263186
[TBL] [Abstract][Full Text] [Related]
17. [14-O-hemiesters and 13-hydrazones of anthracyline antibiotics of the daunorubicin series. Synthesis and cytostatic activity with respect to tumor cells sensitive or resistant to doxorubicin].
Povarov LS; Leont'eva OV; Bernaki PD; Olsuf'eva EN; Salimova EI; Pera P; Preobrazhenskaia MN
Bioorg Khim; 1995 Dec; 21(12):925-32. PubMed ID: 8602889
[TBL] [Abstract][Full Text] [Related]
18. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance.
Veitch ZW; Guo B; Hembruff SL; Bewick AJ; Heibein AD; Eng J; Cull S; Maclean DA; Parissenti AM
Pharmacogenet Genomics; 2009 Jun; 19(6):477-88. PubMed ID: 19440163
[TBL] [Abstract][Full Text] [Related]
19. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
[TBL] [Abstract][Full Text] [Related]
20. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
